CytoCares (Shanghai) Inc.
PrivateLast Round
Series A
Extension
May 12, 2023
Total Funding Raised
$14.48M
Company Overview
CytoCares (Shanghai) Inc. is a biotechnology company that develops first-in-class therapeutics for cancer and autoimmune disease treatment. The company has proprietary immuno-oncology therapeutic platforms, including TriTE™, CCNK™, and CCMφ™, to create antibodies that modulate immune cells to combat cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoCares (Shanghai) Inc. Comps
Public and private peers based on sector, stage, and business model.
CytoCares (Shanghai) Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 12, 2023 |
CytoCares (Shanghai) Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tailong Investment | Series A Extension |
| Shenzhen Capital Group | Series A Extension |
CytoCares (Shanghai) Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CytoCares (Shanghai) Inc.'s valuation, stock price, and market status.
